| Nov 5 |
MacroGenics GAAP EPS of $0.90 beats by $0.81, revenue of $110.7M beats by $23.12M
|
| Nov 5 |
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
|
| Nov 4 |
MacroGenics Q3 2024 Earnings Preview
|
| Nov 1 |
Discover Alpha Tau Medical And 2 Other US Penny Stocks
|
| Oct 30 |
MacroGenics says CEO Scott Koenig to step down
|
| Oct 30 |
MacroGenics Announces Leadership Transition
|
| Oct 29 |
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
|
| Oct 22 |
TerSera Therapeutics to acquire global rights to MARGENZA
|
| Oct 22 |
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
|
| Sep 26 |
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
|
